Christine Wohlfarth

First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial

Mothaffar F. Rimawi, Jean-­Marc Ferrero, Juan de la Haba-Rodríguez et al. · Journal of Clinical Oncology · 2018 · 221 citations

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer

Javier Cortés, Véronique Dièras, Sylvie Lorenzen et al. · JAMA Oncology · 2020 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

Grazia Arpino, Juan de la Haba-Rodríguez, Jean-­Marc Ferrero et al. · Clinical Cancer Research · 2023 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract PD3-02: Final analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer

Grazia Arpino, Juan de la Haba-Rodríguez, Jean-­Marc Ferrero et al. · Cancer Research · 2021 · 27 citations

Medicine, Oncology, Pharmacology +17